Brentuximab vedotin (BV), an antibody–drug conjugate targeting CD30, has shown clinical activity in diffuse large B-cell lymphoma (DLBCL), particularly in CD30-expressing tumors. The gene discussed is TNFRSF8; the disease is diffuse large B-cell lymphoma.